The 24-week PEARL study assessed the lipid-lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients at cardiovascular risk despite their previous lipid-lowering therapies in a real-world setting in Germany

In total, 72.8% of patients reported complete or partial statin intolerance and mean low-density lipoprotein cholesterol was 4.7 mmol/L (180.5 mg/dL) at baseline; enrolled patients received alirocumab dosing of 75 mg or 150 mg every 2 weeks based on physicians’ clinical judgment

In alirocumab-treated patients, low-density lipoprotein cholesterol was reduced from baseline by 48.6% at week 24, including 43.6% of patients remaining on alirocumab 75 mg every 2 weeks throughout; alirocumab was generally well tolerated